Eldelumab
Monoclonal antibody
- none
- 946414-98-8
- none
- 15O91A27I5
- D10404
Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.[3]
This drug was developed by Bristol-Myers Squibb and Medarex.[4]
References
- ^ a b Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. (April 2016). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–28. doi:10.1093/ecco-jcc/jjv224. PMC 4946756. PMID 26721935.
- ^ a b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
- ^ "Eldelumab". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e